Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel targeted immunotherapy for Alzheimer’s disease, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive business update.
The company is entering a high-catalyst period focused on the clinical validation of its lead antibody and the expansion of its next-generation delivery platform.
A central highlight of the update is the continued advancement of sabirnetug (ACU193), the first monoclonal antibody developed to selectively target soluble amyloid-beta oligomers.
Acumen confirmed that the ALTITUDE-AD Phase 2 clinical trial is progressing according to schedule, with topline results expected in late 2026.
This trial is designed to evaluate the efficacy and safety of sabirnetug in patients with early Alzheimer’s disease, building on promising Phase 1 data that demonstrated the drug's ability to engage its target without significant safety signals.
Parallel to its clinical progress, Acumen has significantly strengthened its technological pipeline through its Enhanced Brain Delivery (EBD) program.
The company recently closed a $35.75 million private placement specifically dedicated to the development of EBD candidates.
This program aims to utilize transport technologies to increase the permeability of the blood-brain barrier, potentially allowing for lower systemic dosing and improved patient outcomes.
Acumen targets the submission of an Investigational New Drug (IND) application for its lead EBD candidate by mid-2027.
Financially, Acumen ended 2025 with $116.9 million in cash, cash equivalents, and marketable securities.
Management stated that this capital, combined with the proceeds from the recent private placement, provides a financial runway into early 2027, covering the critical data readout for sabirnetug.
The company reported a net loss of $121.3 million for the full year 2025, driven largely by a planned increase in R&D spending to $104.9 million as the ALTITUDE-AD trial reached peak enrollment activities.